Acupoint injection treatment for non-dialysis dependent chronic kidney disease: A meta-analysis of randomized controlled trials. Issue 51 (18th December 2020)

• Record Type: Journal Article
• Authors: Yang, Tiantian; Zhao, Junnan; Guo, Qi; Wang, Yanfang; Si, Guomin
• Other Names: Cruz. Jorddy Neves section editor.
• Is Part Of: Medicine. Volume 99:Issue 51(2020)
• Publication Date: 2020-12-18
• Subjects: acupoint injection -- non-dialysis dependent chronic kidney disease (non-dialysis dependent CKD) -- meta-analysis -- randomized controlled trial; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000023306
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Aim: To analyze the effects of acupoint injection in the treatment of non-dialysis dependent chronic kidney disease through a systematic review with meta-analysis. Methods: This systematic review with meta-analysis was conducted following the recommendations of the declaration of PRISMA. Full-text literature of randomized controlled trial of acupoint injection therapy for non-dialysis chronic kidney disease was searched in PubMed, Embase, Cochrane Library, China National Knowledge Internet, the Chinese Scientific Journal Database, the Wanfang Database, China Biology Medicine database. The efficacy and safety of acupoint injection for non-dialysis chronic kidney disease were evaluated. Results: Seventeen studies containing 1414 patients met the criteria. The results shows that acupoint injection combined with basic treatment can significantly improve the levels of Ccr (WMD = 4.81; 95% CI:2.54 to 7.08) and Hb (WMD = 4.56; 95% CI:1.72 to 7.39), reduce the levels of BUN (WMD = −0.90; 95% CI: −1.26 to −0.54)and Scr (WMD = −7.66; 95% CI: −12.39 to −2.93), and improve the effective rate (OR = 3.12; 95% CI: 2.29 to 4.26). Conclusion: Our current analysis showed that combined acupoint injection therapy can reduce the levels of BUN and Scr, and increase Ccr and Hb in non-dialysis CKD patients. However, the existing evidence is still insufficient due to the high risk of included trial bias, and future research needs to improve methodological quality. Registration number: CRD42020168143.